Balancing the risks and benefits of infliximab in the treatment of inflammatory bowel disease
Abstract
Patients with moderate to severely active Crohn's disease treated with infliximab may have a small but real risk of developing severe infections, opportunistic infections, and non-Hodgkin's...
Paper Details
Title
Balancing the risks and benefits of infliximab in the treatment of inflammatory bowel disease
Published Date
Jun 1, 2004
Journal
Volume
53
Issue
6
Pages
780 - 782
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History